Table 4 The effects on steatosis of exposure to specific antiretroviral medication in 184 HIV-HCV coinfected patients according to the genotype

Antiretrovirals

n

Adjusted OR

(95% CI)

p

Adjusted OR

(95% CI)

p

Adjusted OR

(95% CI)

p

NRTI

184

NE

NE

NE

zidovudine

144

1.11 (0.542.30)

0.77

0.91 (0.22-3.82)

0.90

1.42 (0.58-3.49)

0.45

lamivudine

161

1.10 (0.442.77)

0.82

0.50 (0.05-5.00)

0.56

1.29 (0.45-3.74)

0.64

stavudine

114

0.96 (0.511.78)

0.88

0.58 (0.14-0.47)

0.46

1.05 (0.51-2.17)

0.89

didanosine

105

1.20 (0.662.18)

0.57

1.02 (0.27-3.93)

0.97

1.17 (0.58-2.37)

0.66

zalcitabine

22

1.68 (0.604.72)

0.33

NE

1.29 (0.41-4.06)

0.66

tenofovir

24

0.87 (0.332.27)

0.78

0.15 (0.01-1.80)

0.13

1.44 (0.49-4.22)

0.51

abacavir

24

0.55 (0.221.39)

0.20

0.40 (0.07-2.40)

0.32

0.58 (0.18-1.84)

0.35

PI

126

1.15 (0.592.24)

0.67

0.19 -0.02-1.76)

0.15

1.46 (0.67-3.15)

0.34

ritonavir

55

0.90 (0.461.75)

0.75

0.54 (0.13-2.28)

0.40

1.04 (0.48-2.27)

0.91

indinavir

68

0.94 (0.511.74)

0.84

1.13 (0.29-4.41)

0.86

0.81 (0.39-1.68)

0.57

nelfinavir

47

0.96 (0.481.89)

0.91

0.37 (0.09-1.56)

0.18

1.19 (0.54-2.66)

0.66

saquinavir

31

0.91 (0.412.00)

0.81

0.41 (0.10-1.72)

0.22

0.94 (0.34-2.61)

0.91

lopinavir-ritonavir

17

0.55 (0.191.63)

0.28

0.45 (0.02-8.11)

0.59

0.67 (0.20-2.19)

0.50

atazanavir

8

0.76 (0.173.43)

0.72

NE

1.70 (0.31-9.24)

0.54

NNRTI

79

0.93 (0.501.74)

0.81

0.33 (0.08-1.27)

0.11

1.38 (0.65-2.95)

0.40

efavirenz

51

1.34 (0.672.69)

0.40

0.74 (0.17-3.27)

0.69

1.77 (0.79-4.00)

0.16

nevirapine

44

0.67 (0.331.35)

0.26

0.34 (0.08-1.38)

0.13

0.80 (0.35-1.83)

0.60